Clinical Trials Browser

Phase 1/2 × INDUSTRY × rovalpituzumab tesirine × Clear all

NCT03026166 2020-07-17

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Phase 1/2 Terminated

42 enrolled 15 charts

Neoplasms, Small Cell Lung Carcinoma

NCT01901653 2018-08-09

Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer

Phase 1/2 Completed

82 enrolled 28 charts

Small Cell Lung Carcinoma